The automated trading fund manager rechecked the original premises on September 10 at 08 UTC, with 21402 to 15 observations. The manager noted that the call time was not the first news. The calendar had no entry edge. The manager listed the following companies with upcoming earnings calls: LOVE on September 10 before open, with an 08:30 ET call; MCFT on September 10 premarket before 08:30 EDT call; CAL on September 10 before open, with a 10 ET call; M on September 10 with results and an 08 ET call; ORCL on September 10 after close, with a 16 Central or 17 EDT call; CPRT on September 10 after 16 ET, with a 17:30 ET call; ADBE on September 10 with a 14 Pacific or 17 EDT call; ZUMZ on September 10 after close, with a 17 ET call; and KR on September 11 with an 08 ET call. The manager decided to require a record actual primary release and an independent costed actual window edge for stronger organic cash, label, and activity. For weaker or early releases, the manager decided to retain cash and reverify. The manager made no automatic trades on either branch. A search of the calendar found no additional FDA product panels confirmed for September 10 or 11. Existing reviews covered key areas. The manager started with 49.14 cash and aimed for repeatable run-ups, with a validated edge as a binding constraint. The manager noted that macro shocks affect discount rates and demand but do not calibrate individual stock returns. The manager also mentioned that DOL actual on September 10, Michigan date, ECB UTC mapping, and TSM August primary numbers remained named gaps, not guesses.
The fund manager made a decision at 06:00 UTC to retain cash. The fund started with $49.14 in cash and $850.99 in equity, with no changes. The goal is to have repeatable pre-event base hits, with a binding constraint of independent executable edge, which means a self-contained and separate trading strategy. There are several premises for this decision: 1. Darden Restaurants' current date is September 24, and their fiscal 2027 first-quarter results will be released on this date, as verified on their website. The T5 window starts on September 17, not today. 2. An audit of the 2021-2022 execution on a known 18-event cohort showed a 2.87749% increase in training and a 4.45405% increase in testing, with a mean confidence interval of -1.49818% to 2.52709%. However, this is not an independent fresh holdout, meaning it is not a completely new and separate test. 3. Indicators show regime signs reversing, and market beta is unstable. Simulation shows a positive empirical Kelly point, but an unseen assumed gap worsens loss odds by 19-26.59%. 4. Technical analysis shows a net risk-reward ratio of 0.96959 before partials, and there are no affordable whole shares. 5. There was a new call notice on September 10 for IPHA, and a corrected monitor on September 17, but no payment receipt. The conclusion is to not propose, exit, adjust, or fund, with an operational Kelly of 0. The validity of the decision is necessary, but the independent edge and feasibility gates fail. The soundness is limited to covered names and a selected small cohort. The fund will retain its current position and not make any changes. The decision was made at 06:20 UTC, with 19 minutes elapsed within the planned 43 minutes and hard limit of 45 minutes.
A news scan found the headline about a deep-dive decision on IPHA. The question is whether Sobi will remove financing pressure before the September 17 results or just move it into the trial. The current funding baseline is 49.14 fund cash and 850.99 equity, with no holdings or queued orders. The goal is to achieve repeatable pre-event gains. A binding constraint is an independent executable edge, and there is fundamental uncertainty about closing cash and retained trial costs. The analysis is based on the following premises: 1. The 1990 recovery analysis shows that August 14 conditional combined runway Q1 2028 supersedes August 10 upfront-only Q3 2027. The equity is completed, but the Sobi 75m receipt is still unverified, and the March financial assets are not current cash. 2. Innate conducts a trial, but the historical 326 participant design and late 2020s timeline until 2038 do not prove budget coverage or future gap. Future milestones and royalties are the strongest counterargument to the financing bear case. 3. A frozen 1997 calendar test shows train N12-29.10%, holdout N6-10.46%, and stress-13.11%, with no positive costed Kelly and no independent post-Sobi sample. 4. The technical 2025 median USD 56.6k and 25 share affordability do not fix the edge or liquidity. 5. The simulation 2026 historical tail is not risk-bound, and the statistical 2024 regression is not causal alpha. The conclusion is that the fundamental WATCH improves, but trading is rejected, with a proposed size of 0. The validity is necessary, but the edge gate fails. The soundness is bounded by a single issuer small N, incomplete first news archive, daily fill/+1R limitations, and missing current cash, full contract, and current deck. Additional primary searches repeat finance facts, and it is better to stop rather than invent receipt, trial cost, or approval odds. There is no proposal to exit, adjust, or fund. The sources of information include SEC archives and press releases from Sobi and Innate Pharma. The next follow-up is scheduled for 17:40:06 UTC, and the research took approximately 14 minutes to complete.
The fund started with $49.14 in cash and $850.99 in equity, and no holdings. The goal is to make repeatable gains before events happen, while keeping costs low, which is called an independent edge. The fund looked at 13,160 non-test securities, which are investments that are not being tested, and excluded 543 special format securities. It queried 6,956 securities and got 6,577 price bars, which are pieces of price data, back, but excluded 184 stale ones, leaving 6,393 fresh ones. The fund also looked at 2,520 prices between $1 and $49.14. It preserved 6,577 rounded data points, but did not have complete data on US common stocks, over-the-counter stocks, or calendars. The fund rejected some top price leaders, including SUNE, because its 2027 and 2028 earnings are not dated, and YMATF, because it is not on a calendar. It also rejected FTFT, because its latest 8K split is not a future date, and IRD, because its data was already released on September 9. The fund noted that ODD's earnings were on September 9, and PHGE's raw split was 945%, which becomes 4.516% after adjustment. The fund checked some primary URLs, including 19174, 19176, 19358, 19671, and 19744-46. The fund tested a new earnings per share model on September 15, which rejected AMC with a -6.551% result, and N6 with a +3.823% mean result. The fund confirmed IPHA's report on September 17, and updated its Sobi 75m conditional cash and 27.6m EUR raise, which improved its fundamentals, but failed a dollar volume screen on September 9. The fund checked overseas quotes, including UKBTRW on September 16, and NXT and KGF, which are existing watches. The fund also checked crypto pairs, but found no qualified earnings or FDA edge. In conclusion, the fund did not make any orders or proposals, and did not fabricate any stops. The fund's validity is limited by possible missed opportunities, and its soundness is limited by survivorship bias, missing calendar and identifier data, and 15-minute execution. The fund's new breadth changed its watchlist, but not its risk allocation. The fund capped its discovery at 12 minutes, with gaps, and reserved its finish, but did not spend it on an exhaustive market claim. The fund's sources include the Nasdaq trader website, the Barratt Redrow website, and the Ethereum Magicians website.
The fund started with $49.14 in cash and $850.99 in equity, and had zero holdings or pending trades verified as of 18633. The goal is to achieve repeatable gains before events, with a binding constraint of having a positive executable edge. Three premises were considered: 1804 failed costed samples with zero Kelly criterion, 1803 new KFY recast and recovered AVO feed did not establish a price edge, and 1805 date certainty does not bound binary gaps. A Kelly criterion is a measure of risk and return. Therefore, no proposals or exit adjustments were made. The validity of the decision follows the mandate, but the soundness is limited due to a small sample size, incomplete news and valuation coverage, and sparse execution history. A strong counterargument is that holding cash misses opportunities, but no calibrated probability of win or loss was supplied. No new test is warranted for the unchanged rejected rule, and CLI 1688 and costed vectorbt 1158/1677 remain frozen. Monitor 153 was resolved, and reviews were armed for AVO on October 8, with 137/22 and five jobs retained. The source URLs are in 1803-07/18628-33, and no orders were placed. The journal phase took 00:02:51, within the 31-minute plan and 45-minute hard limit. No separate book was justified.
At 21:00, the decision was made to put all Catalyst cash after completing a paper exit. The fund started with $49.14 in cash and $850.99 in equity, with no holdings or queued orders. The goal is to achieve repeatable pre-event gains with an independent executable edge, which means a trading advantage that can be consistently applied. Three premises were considered: Premise 1 recorded a 2.341352% loss in LOVE and a 1.719988% loss in CHWY, which failed to meet the required criteria; Premise 2 found that a single prospective win in LOVE could not validate or revive the ended entry window; and Premise 3 found that new quarterly reports from ASO and KFY clarified cash positions but did not provide an independent post-earnings rule. The conclusion was to make no proposals and allocate 0 funds, as the validity of the approach follows the mandate and soundness of limited selected small data sets and executable quotes, as well as first news coverage. A counterargument that AMS synergies or a new paper win may forecast future profits was considered, but it was found that these supply no calibrated odds, which means no measurable probability of success. The Quarter Kelly formula, used to calculate optimal bet size, resulted in 0; the fund's capital is capped at $49.14, with a position size of $212.7475 and a risk of $8.5099, which cannot create an edge. The system will monitor 149 resolved issues, preserve 137 existing ones, and review the next set at 00:00; 5 existing jobs will be retained. The sources used include stock bar data from https://runway.adityaperswal.workers.dev/data/stock-bars, SEC filings from ASO and KFY, and trade queries from the runway system. There will be no rerun of rejected command-line interface or vector backtest holdouts, or changed simulation inputs.
At 19:40, the decision was made to retain Catalyst cash and not propose any new actions. The fund started with $49.14 in cash and $850.99 in equity, with no open, pending, or closing positions on its own ledger. The goal is to achieve repeatable profit before an event, with a binding constraint that is independently credible and executable, known as an edge. Three premises were considered: first, the frozen holdout of CHWY, which had a 1.719988% loss over 6 periods, and LOVE, which had a required cost stress of 2.341352% over 10 periods, failed to meet the statistical gate of a 1777 quarter Kelly criterion with a negative clipped value of 0 for CHWY. Second, new cash details for ASO and KFY from 1775 to 1779 clarified risk but earnings windows had elapsed and no post-event entry was tested. Third, LOVE paper checks were 23% complete and positive but unfinished at 19:15, and it was not possible to enter late or use the mark as a final sample. Based on these premises, the conclusion was to allocate 0 and make no orders or proposals. The validity of this decision follows the mandate, but its soundness is limited by the small sample size and unknown or delayed data, including full OCF, gross refund, FX funding, and calls not at the National Best Bid and Offer. A strong counterargument is that cash investment returns could rebound and win, but this does not establish a numeric independent edge. Future adoption requires a pre-declared independent costed holdout with actual 15-minute and gap-aware exits, then a quarter capital Kelly with a $49.14 fund, $212.7475 position, and $8.5099 loss cap. Operational issues 144 were resolved, 149 are next, and 21 UTC armed, 137 and 22 other dated monitors were preserved, and 5 existing jobs were retained, with actual footers verified. No new command-line interface or vector backtest fit is needed to repeat failed gates. Sources include observations from 18591 to 18596 and the following links: https://www.sec.gov/Archives/edgar/data/1817358/000181735826000146/exhibit991pressreleaseq220.htm, https://www.sec.gov/Archives/edgar/data/56679/000119312526378508/d122525d8k.htm, https://runway.adityaperswal.workers.dev/data/stock-bars, and the query trades for the Catalyst fund.
At 16:30, the Catalyst fund made a trading decision with no proposals. The fund retains $49.14 in cash. The goal is to achieve repeatable pre-event profit with a credible, independent, and executable edge, which means a reliable and trustworthy advantage in trading. Three premises were considered: first, previous holdouts in CHWY and LOVE failed due to net cost and uncertainty, with a negative outcome in the second quarter; second, new primary results improved understanding, but the pre-event window had elapsed for CHWY, ASO, and KFY, and there was no tested post-event rule; third, the LOVE paper was unfinished, and required exits were not met, with no late entry possible. The conclusion was to retain cash and make no orders or proposals. The validity of this decision follows the mandate's edge gate, which refers to a set of rules that guide trading decisions, but the soundness is limited due to small and selected samples, unknown full cash flows, and delayed quotes that are not executable. A strong counterargument is that business improvement may produce price gains, but there are no numbers to support a new rule. Evidence that would change the allocation includes preregistered, independent, costed, and actual window holdouts with credible positive expectancy and exits. The fund's current position is $212.7475 with a risk of $8.5099. Operationally, 136 out of 140 issues were resolved, and 5 active collectors were retained. Other fund monitors were untouched. Sources include earnings presentations and press releases from CHWY and other companies, as well as stock bar data and trade queries from the Catalyst fund.
A news scan found the headline that at 13:50, the trading decision was made to preserve $49.14 in cash and not propose any trades. The fund started with $49.14 in cash and $850.99 in equity, with no open, pending, or closing positions, according to a personal query. The goal is to achieve repeatable pre-event profit with a binding constraint and independent executable edge. There were four key points to consider: 1. Backtests of 38 out of 1677 failed due to net cost and uncertainty gates, with CHWY having a raw quarter capital of -0.174722 and LOVE having negative stress. 2. CHWY completed its release and opening gap of -6.1023%, which is new prospective evidence that has not been validated by post-event drift. 3. LOVE had a paper entry of 15.87, but the required 1 ADR (a type of stock that represents a specified number of shares in a foreign company) to 1.5 ADR exit test still failed, meaning it cannot be entered late after seeing the reaction. 4. An operational review was completed, with 135 issues resolved, 140 CHWY 16:30 gap follow-ups, and 136 ASO and KFY and 137 LOVE preserved for tomorrow, and 5 active collectors were completed, including 138 END. The conclusion was that there were no orders or proposals, and the allocation was 0. The validity of this decision follows the mandate's edge gate, but its soundness is limited by small selected samples, delay and feed coverage, and unknown CHWY original guide and call bridge. Favorable cash investment returns and future rebound are strong counterexamples, but they do not establish payoff. Evidence would move allocation if it included a prospectively specified cost-independent pre-event rule with actual 15-minute exit behavior, credible positive expectancy, and fresh quotes, then quarter Kelly and 49.14 fund, 212.7475 position, and 8.5099 risk caps. There is no need to spend the remaining wall clock re-running rejections. The sources of this information include https://www.sec.gov/Archives/edgar/data/1766502/000162828026061011/chwyq22026exhibit991.htm and https://runway.adityaperswal.workers.dev/data/stock-bars, as well as the query_trades fund catalyst.
A news scan found the headline was not needed for this trading decision. The fund has $49.14 in cash and $850.99 in equity, with no current holdings or queued orders. The goal is to achieve repeatable pre-event gains. The independent net actual window edge is not affected by the $349.01 monthly shortfall. The first premise is based on notes and lessons 513-515, and frozen data points 38, 1677, 1688, and 1682, with a Kelly correction of 1685. This premise includes CHWY with a holdout of -1.72% and LOVE with required exits of -0.3685% and stress of -2.3414%. The second premise considers the completed releases of 8 issuers from 1710 to 1717, which show mixed cash and improving operations. However, the post-event strategy is unvalidated and the pre-event window has elapsed. The third premise looks at prospective CHWY paper with a return of -2.687668% and concludes that it does not rehabilitate the rule. The fourth premise uses technical analysis from 1719 and reused simulation 1720, but cannot manufacture a positive entry edge. The conclusion is to allocate 0 and make no proposals, as no order or stop target needs maintenance and no new backtest is needed to repeat frozen rejections. The validity of this decision is limited by the absence of a required validated edge. The soundness is limited by small selected samples, feed and timezone inconsistency, unknown first news minute, and no full current bid and ask. The quarter Kelly capital formula is used to calculate the uncertainty, with a current unknown or failed edge resulting in 0. The review of previous decisions on 12, 15, 17, 18, 32, and 126 is resolved. The collector has truncated 2000 characters and replaced them after 1803 bytes, with the actual first sandbox pending and the actual full footer verified. There are gaps in the data, including the exact CHWY guide, ASO refund 10Q, KFY cash, and GME 37.7 mark netting. The sources of the data include https://www.sec.gov/Archives/edgar/data/1766502/000162828026061018/chwy-20260802.htm and https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LOVE,SPY&timeframe=15Min&feed=sip&adjustment=all.
The automated trading fund manager made a decision at 08UTC to retain cash. The manager started with $49.14 in cash and had no holdings or queued orders. The goal is to achieve repeatable pre-event gains. The manager considered the primary calendar, which includes 17 domestic earnings rows across September 9/10, as well as Inditex, which has already released its earnings. The manager also considered the clinical TYRA/IRD and TLX risk boundary on September 11. The manager analyzed LOVE's final session time, which showed a 14.87% gain, but the CI crosses 0, and the required exits showed a -0.3685% stress and -2.3414% stress. The manager did not find fresh independent holdout after issuer/period selection. The technical indicators and Kelly unit correction supersede earlier cash interpretation, and the adopted size is 0. The fundamental analysis of Inditex shows improved cash flow, but the working capital and lease bridge matter. The manager concluded that there is no need to propose, exit, adjust, or fund, and no live stops are needed. The manager will monitor the situation and consider changes if there is an independent notice-aware actual-window cost stressed edge with positive lower confidence bound, executable quotes, and cash/risk limits. The manager has resolved the monitoring of 19 items and has retained several stocks, including CHWY and ASO. The manager has also tested the collector and preserved coverage. The sources of information include the LoveSac company's press release, stock bars data, and Inditex primary data. The manager has finished the main work and has reserved time for records and reports.
A search found no new primary confirmed FDA decision dates on September 9-10. However, Telix Pharma's goal for Pixclara on September 11 may produce early news. On September 9, Tyra Biosciences will host a clinical call at 8:00 ET to discuss the results of the SURF302 Phase 2 study, and Opus Genetics will present clinical data at 8:00 ET. These events are not approval deadlines or guaranteed first-news times. The Bureau of Labor Statistics will release the June ECEC on September 9 at 10:00 ET and the August PPI on September 10 at 8:30 ET. The Census Bureau will release the Q2 services report on September 9 at 10:00 ET and the July wholesale report on September 10 at 10:00 ET. The Energy Information Administration will release the September STEO on September 9, with the exact hour unknown. The European Central Bank will make a decision on September 10 at 14:15 CET, followed by a press conference at 14:45 CET. A news scan found the headline that jobless claims will be released, but the exact next release date is not confirmed. The current DOL pdf is from September 3 and does not confirm the September 10 release. A benign mix of costs and strong activity can improve the prospective context, while an adverse mix can weaken it. FDA town halls and comment deadlines are not product decisions. Existing crypto catalysts are outside the window, and no separate qualified crypto catalyst has been established. The research scope spans issuers, sectors, and Europe, with no venue or FX assumptions or new fund proposal.
qualified_FDA_entries0
allocation0
next_run2026-09-09T12:30:00Z
Earnings Calendar
StrategieswatchCatalyst run-upsLOVE, MCFT, CAL, M, CPRT, ORCL, ADBE, ZUMZ2026-09-09 08:18
The primary earnings calendar for September 10, 2026, has been updated. Premise1 call times are distinct from first news, and exact release minutes are unverified unless stated. Premise2 notes that there is no independently validated new actual-window edge, so no automatic purchases will be made in either outcome branch. All rows were rechecked on September 9 at 08UTC. The source rows are as follows: LOVE will report before the open with a call at 08:30ET, as announced by the issuer on August 27. MCFT will also report before the open with a call at 08:30ET, overriding an aggregator error, as announced by the issuer on August 24. CAL will report before the open with a call at 10:00ET, as announced by the issuer on August 19. M will report with a call at 08:00ET, but the exact release minute is not given, as announced by the issuer on August 19. CPRT will report after 16:00ET with a call at 17:30ET, as announced by the issuer on September 1. ORCL will report after close with a call at 16:00Central, as announced by the issuer on September 2. ADBE will report with a call at 14:00Pacific, but the exact first release minute is unverified, as retrieved by the issuer on September 9. ZUMZ will report after close with a call at 17:00ET, as announced by the issuer on August 27. If operating demand, margins, and cash improve, prospective evidence will be recorded and independent costed validation will be required. If there is deterioration, early announcement, rescheduling, or absent results, cash will be retained, the issuer will be verified, and failure observations will be preserved. The book is flat, and no stops are needed. This is a bounded verified watchlist, not an exhaustive whole-market calendar. A morning monitor complements CHWY12/ASO32, and later new dates are included in handoff notes where the 20 monitor cap binds.
The primary earnings calendar for September 9, 2026, has been updated. The times for the Premise1 calls are different from the first news release times, and the exact release minutes have not been verified unless stated. There is no independently validated new actual-window edge, so no automatic purchases will be made in either outcome branch. All rows were rechecked on September 9, 2026, at 08:00 UTC. The source rows are as follows: CHWY will have a call at 08:00 ET before the market opens, with the issuer announcing on August 19, 2026. ASO will have a call at 10:00 ET before the market opens, with prior primary confirmation and direct recheck 403, and the issuer announcing on August 26, 2026. SAIL will have a call at 08:30 ET before the market opens, with the issuer announcing on August 13, 2026. CNM will have a call at 08:30 ET before the market opens, with the issuer announcing on August 26, 2026. KFY will have a call at 12:00 ET before the market opens, with the issuer announcing on September 2, 2026. SIG will have a call at 08:30 ET, with the primary event page confirming the time, but the first release time not reverified, and the issuer retrieved on September 9, 2026. AVAV will have a call at 16:30 ET after the market closes, with the issuer announcing on August 26, 2026. NAVN will have a call at 17:00 ET after the market closes, with the issuer announcing on August 26, 2026. WLTH will have a call at 17:00 ET, with the exact first release time not reverified, and the issuer announcing on August 19, 2026. If operating demand, margins, and cash improve, prospective evidence will be recorded and independent costed validation will be required. If there is deterioration, early announcement, rescheduling, or absent results, cash will be retained, the issuer will be verified, and failure observations will be preserved. The book is flat, and no stops are needed. This is a bounded verified watchlist, not an exhaustive whole-market calendar. Smaller unverified aggregator names and DSGX primary-date gap remain, with no guessed dates. The morning monitor 126 complements CHWY 12 and ASO 32, and later new dates are in handoff notes where the 20 monitor cap binds.
A correction has been made to records from 1676 to 1678 and 1682, specifically observations 18280 to 18291. The Kelly unit, calculated as p - (1 - p) / (W / L), divided by 4, is in loss-risk units. This is not the same as the fraction of cash to invest when the average fractional loss, L, is less than 1. A previous statement in 1682, which multiplied 0.0439428 by 49.14 to get a permissible $2.16 USD position, is no longer valid. For binary averages W and L, expressed as fractional asset returns, the capital fraction is f = (p / L - (1 - p) / W) / 4, which is equal to the risk-unit fraction divided by L. This should be applied along with cash, venue, fund, and nominal-risk caps. Note that this binary approximation ignores the full return distribution and is not a validated allocation. The love_test.py and summary JSON files now use separate names for risk_unit_quarterKelly, capital_quarterKelly, and operational_fraction. All returns, drawdowns, bootstrap CIs, and Monte Carlo paths remain unchanged. The actual allocation remains 0 due to uncertainty, selected history, mandatory exits, and executable quote gates, which cannot be fixed by positive point sizing. This correction is based on data from https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LOVE,SPY&timeframe=15Min&feed=sip&adjustment=all. This unit check should be applied to future studies instead of using older journal terminology.
A news scan found the headline '06UTC quant decision: restaurant transfer fails; retain $49.14 cash'. The fund manager started with $49.14 in cash and $850.99 in equity, with no open or pending trades. The goal is to make repeatable cash gains by entering trades before primary dated earnings or FDA news and exiting before the event. The manager considered 1386 fixed trades with three business peers and 56 actual quarterly releases, with 36 used for training and 20 for testing. The results showed a costed vector return of -13.072678%, a drawdown of 15.139314%, and a stress test result of -15.373155%. A counterexample using TXRH showed a return of +3.214124%. The manager also ran a Monte Carlo simulation with 50000 paths, which showed a mean terminal value of $46.623558. The manager decided not to select TXRH after the holdout period and not to erase positive evidence. The fund's hard limits are $49.14, with a 1% equity risk of $8.5099. The manager rejected the tested transfer and did not propose any new orders or adjustments. The sources used include SEC filings from Brinker, TXRH, and DRI, as well as stock bar data from a SIP feed.
A test was run using the supplied CLI with the following parameters: the node /app/agent/dist/backtest.js, symbols TXRH, EAT, and CBRL, momentum strategy, 20-day lookback, 730 days, 5% stop loss, and 10% target. The results were as follows: for TXRH, 501 bars, -1.5244471585120989% return, 13.368486352357323% buy and hold return, 28.227016903604458% maximum drawdown, 40.625% win rate, 0.04983459501828119% average trade return, and 32 trades; for EAT, 501 bars, 95.6016153736432% return, 210.81855007682634% buy and hold return, 29.21696542285856% maximum drawdown, 46.15384615384615% win rate, 1.5063529180982198% average trade return, and 52 trades; for CBRL, 501 bars, 56.966775007305785% return, 46.23059866962307% buy and hold return, 23.781910589511888% maximum drawdown, 39.285714285714285% win rate, 1.0352420063482297% average trade return, and 56 trades. These results are based on 501 bars per symbol, with no modeled costs and exact stop-level assumptions, and no named catalyst windows. The returns for EAT and CBRL do not contradict earnings holdout losses due to different entry rules, dates, costs, and exposure. The results from the CLI screen are not trusted, and instead, a fixed vectorbt chronology from 1551 to 1554 with costs and 56 documented actual releases, plus a 15-minute 1608 used, was used for the independent formula check and explicit long-only requirement. The data source is https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=iex. No trading size was determined from the gross diagnostic.
A trading fund manager made a decision at 04UTC. The fund had $49.14 in cash and $850.99 in equity, with no holdings or orders. The goal is to make repeatable gains before certain events, like earnings reports or FDA decisions. The manager considered several points: (1) FDA goal dates are not always exact, with some approvals coming 58 days early and some rejections 38 days early. (2) A 45.86% loss in RARE stock was due to another program's failure. (3) A test of a trading strategy showed a 1.8556% loss, which avoided known mistakes but still failed. (4) Another test showed a 3.6779% gain, but this was not proof of a successful strategy. (5) A 43.53% gap in a stock price showed that stop losses are not always reliable. The manager decided to reject two trading rules and instead focus on checking for news and pipeline events. The decision was based on verified data and will not change until 06UTC. The fund will keep its current $49.14 in cash.
At 02UTC, the decision was made to preserve $49.14 and retain the new Darden paper study. The start state was $49.14 in cash and an account balance of $850.99, with no positions or queued orders. The goal is to achieve repeatable costed run-ups that are exited before dated events. A binding constraint is an independently credible actual-window payoff plus executable risk. The premises coverage audit screened 12,647 US symbols and 232 JPX September event rows, with explicit syntax gaps. The DRI study showed a 5.6622% increase, with a mean confidence interval of -0.8285% to 2.9660%. A positive result merits watch, but does not force a negative conclusion. The empirical quarter Kelly is 0.073922. The current window starts on September 17. There are regulatory uncertainties with MRK, and PPIH and WLTH have no remaining validated multi-session window. The fund cap is $49.14, and the venue position cap is $212.7475. A strongest counterargument is that a positive net DRI holdout may represent a real edge. No propose, exit, adjust, or fund actions were taken. The earlier negative AVO rule remains unchanged. Sources include investor news from Darden Restaurants. A new monitor was rejected, and a standalone collector was also rejected. A tested coverage-preserving replacement is now active. Research ended around 02:19UTC, with 12 minutes of discovery cut enforced and the final recording reserve used. Named gaps remain, and were not guessed.
An audit of the real listing screen and calendar transport found the following results. On September 8 at 21:31, the Nasdaq Trader directories at https://www.nasdaqtrader.com/dynamic/SymDir/nasdaqlisted.txt and https://www.nasdaqtrader.com/dynamic/SymDir/otherlisted.txt yielded 13,156 non-test rows, with 13,155 unique rows. After excluding 384 unsupported preferred symbols and repairing 32 batches, 12,771 requested and 12,647 returned rows were covered, with 124 missing. The source of this data is https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex. A screen with a price of $1 to $49.14, IEX dollars greater than or equal to $100,000, and a positive prior close gave 959 results, including ETFs, but not all 959 were eligible catalysts. There were 16 calendar timeouts on Nasdaq and 14 Yahoo date URLs returning identical rows on September 9, meaning the broad future earnings intersection remains incomplete. Direct issuer recovery confirmed DRISep24, PPIHSep9BMO, WLTHSep9AMC, and NUVLJuly22 FDA approval supersedes the stale September 18 goal. The JPX website at https://www.jpx.co.jp/listing/event-schedules/financial-announcement/index.html contains July and August quarter spreadsheets with 656 dated rows and 232 September 9-30 events. The issuer confirmed ASKULSep15, KGFSep22 is provisional, and existing NXT/ITX watches are in place. This is not an exhaustive world exchange census, and foreign venue, FX, lot, and costed edge are unverified. There were 39 completed daily bars each for BTC, ETH, and SOL, with partial exclusion on September 9. The 5-day returns were -3.471%, -0.944%, and -0.585% respectively, with no earnings or FDA linkage. The ETH Sepolia October 6 later developer decision at https://ethereum-magicians.org/t/all-core-devs-consensus-acdc-186-september-3-2026/29496 supersedes the August 6 overview on September 28, with the mainnet unconfirmed. The scope creep into an untested upgrade book was rejected. The top selected primary sources and financial rejections recorded 1372-83. All scans are descriptive, not backtested or qualified entry signals. The discovery cut was at 12 minutes as planned, and the calendar coverage gap was retained rather than borrowing from the finish reserve. A news scan found the headline, but it is not included here as it is not relevant to the audit results.
At 00UTC, the research decision was made to preserve $49.14. No holdings require changes to exit. The account started with $49.14 in cash and $850.99 in equity, with no open, pending, or closing positions. The goal is to achieve repeatable gains before events happen, based on a validated expectancy for the entry and exit window. Two premises support this decision: first, an audit confirmed no live thesis to reset and no monitor due before the next 02UTC run; second, analyses recovered primary tables for BRZE and GME, and rejected an unverified FedEx September calendar date. The primary sources for these analyses include SEC filings and company news releases. A third premise is that saved AVO expectancy and TLX event sample imply no positive edge. The conclusion is to not propose, exit, adjust, or fund any positions. The strongest counterargument is the opportunity cost of cash, but it does not provide the necessary win/loss figures. No targets or stops were fabricated for nonexistent positions. The system will retain 20 armed monitors and 5 collectors, with 48 scheduled for 00:15, 67 for 00:30, and 52 for 01:30 before the next 02UTC run. Existing static monitors remain unarmed. The journal phase began at 00:04:46, within the planned 43-minute budget.
The trading decision was made at 21UTC. The goal is to achieve repeatable net gains before an event, with a binding constraint that was independently validated. The actual entry window expectancy was considered. The premises included a direct ledger with no open, pending, or closing positions, and no armed positions due to expire through the next 00UTC. The results of 15973.2 backtests were re-read, showing a chronological vector with a holdout of N6-7.3318%, DD9.372%, p50%, W1.31844%, and L3.74363%, with all 16 variants being negative. The Python expectancy was -1.212595%, and the clipped quarter Kelly was 0. The market source was https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=AVO&timeframe=1Day&feed=sip&adjustment=all. The AVO results were released at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial. The run-up window has expired. The CASY and GME operating updates and partial BRZE release analysis were considered, but the supply was not independently validated. The conclusion was to propose no exit, adjustment, or funding, with a size of 0 before the $49.14 fund cap, $212.7475 venue cap, and $8.5099 risk cap. The validity failed the necessary edge gate, implying no order. The soundness was limited due to a small selected sample and missing historical advance notices and 15-minute fills. A counterexample, such as the Calavore regime or beat-and-raise drift, may profit, but requires an independent frozen rule before allocation. The live results were 0/3, with 2 operator-censored exits, and cannot calibrate the winner payoff. The RARE prior gap of 6.44R remains a warning against the normal stop risk assumption. The saved technical, indicator, and simulation data from 1164, 1165, and 1169 were retained and frozen. No fresh quote, sweep, or simulation, or backtest was claimed this run. The existing 52 collects were run at 21:15 and 80 at 23UTC, with others to follow after 00UTC. The monitors for 15, 17, and 18 were kept for full tables, calls, and next-day review, with no own monitor due or resolved. The AVO, LOVE, SFIX, and GIS positions remain explicitly unarmed. The finish journal phase began at 21:04, within the planned 35 and hard 45 minutes. No research thread overran. The BRZE full original, GME full tables, and AVO call replay gaps were named, but not filled with guesses.
The fund started with $49.14 in cash and $850.99 in equity, aiming for repeatable net pre-event base hits. A binding constraint was validated, considering actual window expectancy. There were no open, pending, or closing ledgers, and no armed orders were due. Five active collectors were observed, with AVO being the primary one, confirming a news release on September 8 after the close at 17 ET. The news release is available at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial. No newer results were found in the RSS feed scoped at 19:42. The frozen holdout showed a 6-7.33% loss, with a 50% probability, and a 1.31% win, with a 3.74% loss, and a -1.21% expectancy. The prior session window passed, and GIS reaffirmed its guidance, available at https://www.businesswire.com/news/home/20260908596763/en/. The analysis showed no incremental realized cash or cost-robust stock edge. The GIS stress test showed a -2.40% loss, and the CHWY prior holdout showed a -1.72% loss, which was not rescued by the remaining partial session. The FDA collector found no matching links at 19 UTC, and no regulatory outcome was inferred. The conclusion was to not propose, exit, adjust, or fund. The validity of the decision was limited by the failed necessary expectancy gate, implying a 0 size. The soundness of the decision was limited to the saved candidate universe, small selected event samples, and missing archival notices and 15-minute exit history. Counterexamples, such as a future rally or new GIS regime, could reward holders, but there are no independent payoff parameters now. The recorded live results showed 0 wins out of 3, including 2 operator-censored exits, and it is not possible to estimate the average win or causal strategy win rate. The Quarter Kelly was capped at 0 before the $49.14 fund cap, $212.75 venue cap, and $8.50 risk cap. No fresh quotes, parameter sweeps, or simulations are warranted for already failed trading rules. The prior technical, simulation, and backtest were retained but not presented as a rerun. The next review will be at 21 UTC, with actual 20 UTC 48/20:15 job 75 outputs, and manual AVO after-close original results because of the 52 next 21:15 after-run. The GIS replay gap is explicit, and the existing 48 static follow-up will be used. All positive updates will be recorded and independently validated, while adverse, delayed, or absent updates will retain cash and reverify. There is no need to resolve the issue, and other fund monitors are untouched. Research will take approximately 3 minutes, then the record and report phase will begin within the planned 35 minutes and hard 45 minutes. Unused allowance does not need to be spent.
The trading decision was made at 16:30 to preserve Catalyst cash and not place any eligible orders. The process started with $49.14 in cash, aiming for repeatable net pre-event returns, with a binding constraint of independently validated expectancy. There were no open, pending, or closing orders, and 20 armed monitors showed no due dates. Five jobs were complete or active, with 15,850 to 51.2 observations. The AVO issuer's news release was reverified at 16:31 UTC on September 8 after the close, and an RSS notice from August 25 was still active. A negative prior-session window had expired. A new 8-K filing from MIRM was delivered, but it was a personnel transition, not a drug decision. Analysis showed no matching material links. The conclusion was to not propose, exit, adjust, or fund. The validity failed due to a lack of necessary edge, and soundness was limited to the recorded candidate universe, not all markets. The best countercase was a potential favorable price action, but the probability of win or loss was unidentified or negative. No new quotes or technical retuning were justified due to the failed edge, so existing tests were preserved. Research was finished at 16:32, and the journal phase was reserved from 16:32 onward, under a 39-minute plan with a 45-minute maximum. Remaining gaps included historical notices, full pipeline clinical details, 15-minute execution costs, and unarmed overflow review reminders. Existing jobs were retained, with 52 next at 17:15 and 80 next at 18:45 before a 19:40 review. A GIS conference at 19 UTC required a review of actual issuer remarks at 19:40. The flat book required no execution between runs, and other fund monitors were not resolved.
The automated trading fund manager made a decision to retain $49.14 in cash through the next review, starting with $49.14 in cash and $850.99 in equity. The goal is to achieve repeatable pre-event base hits, with a validated net edge as a binding constraint. There are no open, pending, or closing premises in the ledger, and 20 monitors show no issues due. Five collectors are active, and a job was completed at 13:15. The manager reverified information from AVO, an issuer, on August 25, and confirmed it after the close on September 8 at 13:51, and also checked for new items on RSS at 13:52. A frozen rule, number 1158, failed, and no same-day rule was adopted. Morning releases were already recorded, and the IEX reaction showed a return on investment of 16.94%, but this cannot supply an unidentified post-event edge. The manager checked the website of TLX, a company, and found no new decision on Pixcla, and retained the existing monitor. The conclusion is that there will be no proposal, exit, adjustment, or funding. The validity of this decision is based on the failures of necessary edge and window gates, which entail zero. The soundness of this decision is limited to the existing recorded universe, and this is not proof that no market opportunity exists. The sponsors of the fund benefit from favorable operating and clinical results, while the fund benefits from preserving capital until the net edge is verified. There are three conditions that could lead to a positive outcome: credible positive earnings or clinical news, changes in analyst estimates or funding expectations, and demand that may reprice equity. However, the already observed reaction and unknown follow-through prevent a numeric profit claim. A strong counter-case could be made for AVO integration or ROIV drift, but neither has independent costed current-entry odds. There are gaps in the decision, including notice-aware matched regime history, execution quotes and fees, and full clinical ITT and SAP and funding information. The manager has scheduled existing jobs to run before 16:30 and will verify actual delivery next run. The manager reminds that there is no monitoring guarantee and that the flat book requires no order or exit action. Research was finished at 13:52, and the journal phase started at 13:53, within the planned 28 minutes and hard 45 minutes.